Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taroh Satoh

Showing results (31-40 of 277) with videos related to

Pageof 28
Sort By:
Cancer Science|September 11, 2012
Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumorsIsamu Okamoto, Tokuzo Arao, Masaki Miyazaki, et al.
International Journal of Clinical Oncology|July 7, 2023
Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)Hiroki Yukami, Hisato Kawakami, Toshifumi Yamaguchi, et al.
Japanese Journal of Clinical Oncology|February 14, 2012
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancerMegumi Ishiguro, Toshiaki Watanabe, Kensei Yamaguchi, et al.
Investigational New Drugs|May 26, 2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancerTaroh Satoh, Kensei Yamaguchi, Narikazu Boku, et al.
BMC Cancer|June 27, 2019
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, et al.
Japanese Journal of Clinical Oncology|April 29, 2014
Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in JapanKensei Yamaguchi, Toshiaki Watanabe, Taroh Satoh, et al.
Anticancer Research|August 19, 2007
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancerTomohiro Ozaki, Kenji Tamura, Taroh Satoh, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2009
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumorsToshio Shimizu, Isamu Okamoto, Kenji Tamura, et al.
BMC Cancer|October 17, 2021
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic riskMototsugu Shimokawa, Toshinobu Hayashi, Junichi Nishimura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2009
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trialTakayasu Kurata, Tatsuhiko Kashii, Koji Takeda, et al.
Pageof 28

Showing results (31-40 of 277) with videos related to

Sort By:
Pageof 28
Cancer Science|September 11, 2012
Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumorsIsamu Okamoto, Tokuzo Arao, Masaki Miyazaki, et al.
International Journal of Clinical Oncology|July 7, 2023
Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)Hiroki Yukami, Hisato Kawakami, Toshifumi Yamaguchi, et al.
Japanese Journal of Clinical Oncology|February 14, 2012
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancerMegumi Ishiguro, Toshiaki Watanabe, Kensei Yamaguchi, et al.
Investigational New Drugs|May 26, 2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancerTaroh Satoh, Kensei Yamaguchi, Narikazu Boku, et al.
BMC Cancer|June 27, 2019
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, et al.
Japanese Journal of Clinical Oncology|April 29, 2014
Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in JapanKensei Yamaguchi, Toshiaki Watanabe, Taroh Satoh, et al.
Anticancer Research|August 19, 2007
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancerTomohiro Ozaki, Kenji Tamura, Taroh Satoh, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2009
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumorsToshio Shimizu, Isamu Okamoto, Kenji Tamura, et al.
BMC Cancer|October 17, 2021
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic riskMototsugu Shimokawa, Toshinobu Hayashi, Junichi Nishimura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2009
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trialTakayasu Kurata, Tatsuhiko Kashii, Koji Takeda, et al.
Pageof 28